The estimated Net Worth of John D Young is at least $18.2 Million dollars as of 8 March 2023. Mr. Young owns over 1,372 units of Pfizer stock worth over $327,179 and over the last 12 years he sold PFE stock worth over $8,944,989. In addition, he makes $8,959,380 as Chief Business Officer and Group President at Pfizer.
Sign up
Mr. Young PFE stock SEC Form 4 insiders trading
John has made over 23 trades of the Pfizer stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 1,372 units of PFE stock worth $87,067 on 8 March 2023.
The largest trade he's ever made was exercising 163,334 units of Pfizer stock on 25 February 2021 worth over $3,738,715. On average, John trades about 6,526 units every 16 days since 2012. As of 8 March 2023 he still owns at least 11,031 units of Pfizer stock.
You can see the complete history of Mr. Young stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Young biography
John D. Young serves as Chief Business Officer, Group President of the Company. Primary Care Business Unit’s Regional President for Europe and Canada from 2009 until June 2012. Director of Johnson Controls International plc. Mr. Young represents Pfizer as a member of the Board of Directors of the GSK Consumer Healthcare joint venture.
What is the salary of John Young?
As the Chief Business Officer and Group President of Pfizer, the total compensation of John Young at Pfizer is $8,959,380. There are 3 executives at Pfizer getting paid more, with Albert Bourla having the highest compensation of $17,929,000.
How old is John Young?
John Young is 55, he's been the Chief Business Officer and Group President of Pfizer since 2019. There are 19 older and 7 younger executives at Pfizer. The oldest executive at Pfizer Inc. is Wyllie Don Cornwell, 72, who is the Independent Director.
What's John Young's mailing address?
John's mailing address filed with the SEC is C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN, CT, 06511.
Insiders trading at Pfizer
Over the last 12 years, insiders at Pfizer have traded over $216,003,942 worth of Pfizer stock and bought 24,324 units worth $872,198 . The most active insiders traders include Shantanu Narayen, Ian C Read, and James M Kilts. On average, Pfizer executives and independent directors trade stock every 12 days with the average trade being worth of $2,169,896. The most recent stock trade was executed by Jennifer B. Damico on 13 August 2024, trading 5,154 units of PFE stock currently worth $147,714.
What does Pfizer do?
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.
What does Pfizer's logo look like?
Complete history of Mr. Young stock trades at Johnson Controls International plc, Pfizer, and Arvinas Inc
Pfizer executives and stock owners
Pfizer executives and other stock owners filed with the SEC include:
-
Albert Bourla,
Chairman of the Board, Chief Executive Officer -
Frank D'Amelio,
Chief Financial Officer, Executive Vice President - Business Operations and Global Supply -
Mikael Dolsten,
Chief Scientific Officer, President - Worldwide Research, Development and Medical -
John Young,
Chief Business Officer, Group President -
Dr. Albert Bourla D.V.M., DVM, Ph.D.,
Chairman & CEO -
Frank A. D'Amelio,
CFO & Exec. VP -
Dr. Mikael Dolsten M.D., Ph.D.,
Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical -
Angela Hwang,
Group Pres of Biopharmaceuticals Group -
John D. Young,
Advisor -
Shantanu Narayen,
Lead Independent Director -
Wyllie Don Cornwell,
Independent Director -
Helen Hobbs,
Independent Director -
Suzanne Nora Johnson,
Independent Director -
Joseph Echevarria,
Independent Director -
James Kilts,
Independent Director -
Ronald Blaylock,
Independent Director -
Dan Littman,
Independent Director -
Scott Gottlieb,
Independent Director -
James Quincey,
Independent Director -
Susan Hockfield,
Independent Director -
Susan Desmond-Hellmann,
Director -
Gordon Loh,
Senior Vice President, Corporate Audit -
Jennifer Damico,
Senior Vice President, Principal Accounting Officer, Controller -
Sally Susman,
Chief Corporate Affairs Officer, Executive Vice President -
Alexander Mackenzie,
Executive Vice President, Chief Development Officer -
Douglas Lankler,
Executive Vice President, General Counsel -
Rady Johnson,
Chief Compliance, Quality and Risk Officer, Executive Vice President -
Lidia Fonseca,
Executive Vice President, Chief Technology Officer and Digital Officer -
Dawn Rogers,
Chief Human Resource Officer, Executive Vice President -
Angela Hwang,
Group President, Pfizer Biopharmaceuticals Group -
Rady A. Johnson,
Exec. VP and Chief Compliance, Quality & Risk Officer -
Douglas M. Lankler,
Exec. VP & Gen. Counsel -
Christopher J. Stevo CFA,
Sr. VP & Chief Investor Relations Officer -
Lidia L. Fonseca,
Exec. VP and Chief Digital & Technology Officer -
Jennifer B. Damico,
Sr. VP, Controller & Principal Accounting Officer -
Mike McDermott,
Chief Financial Officer -
William Pao,
Executive Vice President -
Stephen W Sanger,
Director -
Frances D Fergusson,
Director -
James C Smith,
Director -
Laurie J Olson,
Executive Vice President -
W Don Cornwell,
Director -
Loretta V Cangialosi,
Sr. Vice President, Controller -
Charles H Hill,
Executive Vice President -
Dennis A Ausiello,
Director -
Kirsten Lund Jurgensen,
Executive Vice President -
Ian C Read,
Chairman & CEO -
Freda C Lewis Hall,
Executive Vice President -
Aamir Malik,
Executive Vice President -
Christoffel Boshoff,
Executive Vice President -
Michael Goettler,
Group President -
Cyrus Taraporevala,
Director -
Iii William H Gray,
Director -
M Anthony Burns,
Director -
Cavan M. Redmond,
Group President -
Kristin C Peck,
Executive Vice President -
David S Simmons,
Business Unit President -
Geno J Germano,
Business Unit President -
Anthony J Maddaluna,
Executive Vice President -
Olivier Brandicourt,
Business Unit President -
Marc Tessier Lavigne,
Director -
George A Lorch,
Director -
Amy W Schulman,
Executive Vice President -
Constance J Horner,
Director -
Payal Sahni,
Executive Vice President -
William R Jr Carapezzi,
Executive Vice President -
Michael Mc Dermott,
Executive Vice President -
David M Denton,
Chief Financial Officer & EVP